JRP Bio granted Korean patent for immune-enhancing use of SH003
“Composition for enhancing immunity comprising a mixed herbal extract,” Korean Patent No. 10-2940993
JRP Bio (Jaein R&P Co., Ltd.) announced that the patent on the immune-enhancing use of its botanical drug candidate SH003 has been granted in Korea (Korean Patent No. 10-2940993, “Composition for enhancing immunity comprising a mixed herbal extract”).
SH003 is an oral botanical drug candidate that standardizes a new combination of herbs based on a Korean medicine formula. It induces selective cancer cell death without toxicity to normal cells while activating the immune system; the new patent protects its immune-enhancing effect.
The company has completed a human study on immune function and is reviewing registration as an individually recognized functional ingredient. With this grant, JRP Bio holds 14 granted Korean patents, all owned by Jaein R&P Co., Ltd.
About JRP Bio
JRP Bio (Jaein R&P Co., Ltd.) standardizes Korean medicine formulas and natural products, builds the evidence behind them, and secures approval to turn them into products people actually use. JRP stands for “Journey from Research to People.” The company received Korea's first IND for an oral botanical anticancer candidate, SH003, and holds 14 granted Korean patents and 42 SCI(E) publications.
Media contact
- Email bs@jrpbio.com
- Phone +82-2-6925-5568